Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AK
Akebia Therapeutics, Inc.
AKBA
Mkt Cap
$186.2M
Volume
6.79M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AK
AKBA
AK
Akebia Therapeutics, Inc.
AKBA
News
·
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Mkt Cap
$192.7M
Volume
6.79M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developments include Phase I initiation of AKB-9090, Phase II trial preparations for LSALT peptide, and anticipated Phase III data from AstraZeneca's ARTEMIS trial in H2 2026.
GlobeNewswire Inc. · Jun 23, 2026
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its Q4 and full year 2025 financial results on February 26, 2026, followed by a conference call at 8:00 a.m. EST to discuss financial results and recent business highlights.
GlobeNewswire Inc. · Feb 19, 2026
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company, focused on kidney disease treatments, will discuss its pipeline outlook including Vafseo prescribing expansion and Praliciguat Phase 2 clinical trial progress.
GlobeNewswire Inc. · Feb 4, 2026
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Benzinga · Dec 1, 2025
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.
GlobeNewswire Inc. · Nov 6, 2025
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.
GlobeNewswire Inc. · Jul 8, 2025
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
Averoa, a biopharmaceutical company, has received European marketing authorization for its oral therapy XOANACYL, which addresses iron deficiency and hyperphosphatemia in chronic kidney disease patients.
GlobeNewswire Inc. · Jun 16, 2025
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that it will present three posters at the European Renal Association Congress 2025.
GlobeNewswire Inc. · May 28, 2025
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
Averoa, a biopharmaceutical company, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its oral therapy XOANACYL, which is used to treat chronic kidney disease.
GlobeNewswire Inc. · Apr 2, 2025
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Akebia Therapeutics, a biopharmaceutical company, announced the pricing of its $50 million public offering of 25 million shares of common stock at $2 per share. The offering is expected to close on March 21, 2025.
GlobeNewswire Inc. · Mar 20, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AK
AKBA
Akebia Therapeutics, Inc.
Buy
Sell
Market
Limit
Soon
AKBA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AKBA yet.
Related Tickers
Earnings